Fiche personne


Directeur général de l'Institut de Cancérologie de Lorraine

Territoire

Lorraine

Statut

Hospitalo-Universitaire

Projets


Publications


High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.

Hennequin C, Sargos P, Roca L, Silva M, Latorzeff I, Peiffert D, Cozzi S, Benyoucef A, Hasbini A, Supiot S, Ronchin P, Wachter T, Azria D, Magne N, Zibouche M, Vial N, Cormier L

Lancet Oncol. 2026 09;27(9):1158-1167

Interpretable AI to predict anal cancer local failure at 3 years with the FFCD Anabase prospective multicentric cohort.

Raynaud C, Vendrely V, Quero L, Lemanski C, Pommier P, Le Malicot K, Saint A, Rivin Del Campo E, Regnault P, Baba-Hamed N, Ronchin P, Crehange G, Tougeron D, Menager-Tabourel E, Diaz O, Hummelsberger M, Minsat M, Drouet F, Larrouy A, Peiffert D, Lievre A, Zasadny X, Hautefeuille V, Mornex F, Lepage C, Bibault JE

Radiother Oncol. 2026 08 4;223:111715

Radioenhancing Hafnium Oxide Nanoparticles (NBTXR3) Followed by Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma and Liver Metastases (NBTXR3-103): Phase 1 Dose-Escalation Trial.

Chajon E, Pracht M, Rolland Y, Nguyen F, Bronowicki JP, Durand-Labrunie J, Vendrely V, Cunha AS, Laurent V, Rio E, Sourd SL, Gustin P, Said PC, Dimitriu M, Facer BD, Vivar OI, Peiffert D, Deutsch E, de Baère T

Adv Radiat Oncol. 2026 01;11(1):101937

Voir plus